Robert C Patio
Overview
Explore the profile of Robert C Patio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bourne C, Raniszewski N, Kulkarni M, Exconde P, Liu S, Yost W, et al.
bioRxiv
. 2025 Mar;
PMID: 40060427
Caspases are a family of cysteine proteases that act as molecular scissors to cleave substrates and regulate biological processes such as programmed cell death and inflammation. Extensive efforts have been...
2.
Dagotto G, Colarusso A, Patio R, Li D, Anioke T, Giffin V, et al.
J Immunother Cancer
. 2024 Dec;
12(12).
PMID: 39694702
Background: Neoantigens are promising immunogens for cancer vaccines and are often delivered as adjuvanted peptide vaccines. Adenoviral (Ad) vectors have been shown to induce strong CD8 T cell responses as...
3.
Jacob-Dolan C, Lifton M, Powers O, Miller J, Hachmann N, Vu M, et al.
iScience
. 2024 Apr;
27(5):109716.
PMID: 38655202
The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces...
4.
Lasrado N, Collier A, Miller J, Hachmann N, Liu J, Anand T, et al.
Sci Adv
. 2024 Feb;
10(8):eadj9945.
PMID: 38394195
Messenger RNA (mRNA) vaccines were highly effective against the ancestral SARS-CoV-2 strain, but the efficacy of bivalent mRNA boosters against XBB variants was substantially lower. Here, we show limited durability...
5.
Lasrado N, Collier A, Hachmann N, Miller J, Rowe M, Schonberg E, et al.
Vaccine
. 2023 Oct;
41(47):6904-6909.
PMID: 37872011
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that BA.2.86 might evade neutralizing...
6.
Lasrado N, Collier A, Miller J, Hachmann N, Liu J, Sciacca M, et al.
bioRxiv
. 2023 Feb;
PMID: 36747640
The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 includes the G252V and F486P mutations. XBB.1.5...
7.
Miller J, Hachmann N, Collier A, Lasrado N, Mazurek C, Patio R, et al.
N Engl J Med
. 2023 Jan;
388(7):662-664.
PMID: 36652339
No abstract available.